TL;DR: 5-Amino-1MQ is a small molecule — not a peptide — that blocks an enzyme called NNMT. NNMT consumes two things the cell needs: nicotinamide, a precursor for NAD+, and SAM, the cell's methyl donor. Blocking the enzyme is a strategy for preserving both pools rather than supplying more. Preclinical fat-tissue work links NNMT inhibition to increased energy expenditure and changes in fat mass. The evidence is cells and rodents; no approval anywhere. Research use only.
What It Is, and What It Is Not
5-Amino-1-methylquinolinium inhibits nicotinamide N-methyltransferase — NNMT. It is studied alongside metabolic peptides because the pathway it touches connects directly to NAD+ availability and fat-cell biology.
But it is worth being blunt about a point that gets blurred constantly: 5-Amino-1MQ is not a peptide. It is a small synthetic molecule, not a chain of amino acids. It appears in peptide catalogues because it is studied in the same metabolic context and sold through the same channels, not because it belongs to the same chemical class.
That distinction has real consequences for stability, handling, and storage, covered further down.
What NNMT Does
NNMT catalyses one reaction, and understanding it explains everything else about this compound.
The enzyme takes nicotinamide — a precursor the cell uses to build NAD+ — and attaches a methyl group borrowed from SAM (S-adenosyl methionine), the cell's universal methyl donor. Both inputs are consumed. The product is excreted.
So a single enzyme drains two separate resources at once:
- Less nicotinamide remains available for NAD+ production.
- Less SAM remains available for the cell's many other methylation reactions, which include the ones that regulate gene expression.
NNMT is especially active in fat tissue and the liver, and published work reports its activity climbing in metabolic disease states — which is what made it a target rather than a curiosity.
Why Block It?
The logic is straightforward. If NNMT is the enzyme draining the pools, inhibiting it should preserve both NAD+ raw material and methylation capacity, without needing to supply either from outside.
The connection between NNMT activity and metabolic dysfunction was reported by Kraus and colleagues in 2014 in Nature. Subsequent work has broadened the picture, but the great majority of it remains in cell and animal models.
In preclinical fat-tissue studies, NNMT inhibition has been associated with increased energy expenditure, shifts in how fat cells handle fuel, and changes in fat mass.
A Different Strategy From NAD+ Supplementation
This is the most useful thing to understand about where 5-Amino-1MQ sits, because it is routinely lumped in with NAD+ precursors as though they did the same job.
| Approach | Strategy | Examples |
|---|---|---|
| Supply the precursor | Add raw material to the pool directly | NAD+, NMN, nicotinamide riboside |
| Inhibit the consumer | Stop an enzyme from draining the existing pool | 5-Amino-1MQ (NNMT inhibition) |
One fills the bucket; the other patches a leak. They are complementary in principle rather than interchangeable, and whether either meaningfully changes outcomes in humans is unresolved. Our NAD+ research overview covers the supply side, and MOTS-c approaches metabolic signalling from a third direction.
What Remains Unknown
The mechanism is clean and well described. The outcomes record is not.
- No completed human trials. The evidence is cell culture and rodent models, and rodent metabolic findings have a poor record of translating intact.
- Selectivity questions. SAM is the methyl donor for a great many reactions, including epigenetic regulation. Preserving the SAM pool is the intended benefit, but the downstream consequences of shifting methylation capacity broadly are not fully characterized.
- No established dosing, kinetics, or safety profile in humans, because the trials that would produce them have not been run.
Handling and Storage
Being a small molecule rather than a peptide makes this compound noticeably easier to work with. It is chemically far more stable than peptide products and tolerates room-temperature storage as a dry powder — no cold chain, and none of the freeze-thaw caution that lyophilized peptides demand.
Solution stability depends on pH and the chosen vehicle. For in-vitro work researchers typically dissolve it in DMSO. It does not require bacteriostatic water reconstitution the way peptide vials do, so the usual reconstitution calculator workflow does not apply in the same form.
Helix North supplies 5-Amino-1MQ 50 mg and 150 mg for laboratory research, with third-party Certificates of Analysis published where available — see our lab testing and CoA page for methodology, or the Canadian research peptides overview for the wider catalog.
For Research Use Only
Everything above describes preclinical cell and animal research on a compound with no completed human trials and no regulatory approval. Helix North supplies 5-Amino-1MQ for research applications only — not for human or animal consumption, and nothing here constitutes medical, dosing, or clinical guidance.
